Skip to content
ChickenStockChickenStock
ResearchENTX
Entera Bio logo

Entera Bio (ENTX) stock

NASDAQ

$3.01-0.33%(-0.01)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-18.07x

Net loss — not comparable

P/B

1.91x

P/S

524.00x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income decreased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 6, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

5 SEC filings
  • Germano Geno JDirector · Aug 7, 2026Grant or award25,014 shares · $0
    Avg. price $065,014 shares held after
  • Malca YonatanDirector · Aug 7, 2026Grant or award22,815 shares · $0
    Avg. price $0100,231 shares held after
  • Taitel HayaDirector · Aug 7, 2026Grant or award20,790 shares · $0
    Avg. price $0119,269 shares held after
  • Ellis SeanDirector · Aug 7, 2026Grant or award20,034 shares · $0
    Avg. price $0208,132 shares held after
  • Rubin Steven DDirector · Aug 7, 2026Grant or award19,117 shares · $0
    Avg. price $034,117 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Entera Bio (ENTX) stock information

NASDAQ

Entera Bio (ENTX) is listed on NASDAQ. Its market capitalization is about $524M. On trailing-twelve-month earnings the P/E ratio is -18.07, and the P/B ratio is 1.91. Return on equity is -10.6%. These figures are computed in-house from official filings and are reference information only.

Entera Bio — frequently asked questions

What is the P/E ratio of Entera Bio (ENTX)?
On a trailing-twelve-month basis, ENTX trades at a P/E ratio of -18.07. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Entera Bio?
ENTX has a market capitalization of about $524M. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.